EUVIMEDEUVIMED entdecken
Kommentar

The KRAS tour: Studying metabolic reprogramming in isogenic pancreatic cancer organoids

Shree Bose, Xiling Shen

Cell Stem Cell · 2024

DOI: 10.1016/j.stem.2023.12.010 ↗

Kurz gefasst

Kommentar in der Zeitschrift Cell Stem Cell, 2024. Verfasst von Shree Bose und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, University of Chicago, Chicago, IL, USA. Hauptthemen laut MEDLINE: Metabolic Reprogramming, Pancreatic Neoplasms. Die Arbeit nennt 10 Literaturangaben. Gefördert von: NCI NIH HHS, NIGMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Metabolic ReprogrammingPancreatic NeoplasmsHumansLipid MetabolismOrganoidsProto-Oncogene Proteins p21(ras)

Substanzen

KRAS protein, humanProto-Oncogene Proteins p21(ras)

Autor:innen und Institutionen

  • Department of Internal Medicine, University of Chicago, Chicago, IL, USA.
  • Terasaki Institute for Biomedical Innovation, Los Angeles, CA, USA. Electronic address: xiling.shen@terasaki.org.

Förderung

  • NCI NIH HHS
  • NIGMS NIH HHS

Zitieren

APA

Bose, S., & Shen, X. (2024). The KRAS tour: Studying metabolic reprogramming in isogenic pancreatic cancer organoids. Cell Stem Cell. https://doi.org/10.1016/j.stem.2023.12.010

Vancouver

Bose S, Shen X. The KRAS tour: Studying metabolic reprogramming in isogenic pancreatic cancer organoids. Cell Stem Cell. 2024. doi:10.1016/j.stem.2023.12.010

BibTeX
@article{Bose2024,
  author = {Bose, Shree and Shen, Xiling},
  title = {The KRAS tour: Studying metabolic reprogramming in isogenic pancreatic cancer organoids},
  journal = {Cell Stem Cell},
  year = {2024},
  doi = {10.1016/j.stem.2023.12.010}
}
Kostenlos starten →